Article and Video CATEGORIES
How should we conduct trials of targeted therapies in lung cancer if large randomized trials require hundreds to thousands of patients, cost millions of dollars and years to conduct, but are extremely likely to have negative results and will require a more refined population with a prospectively defined target? We'll tackle that question in our upcoming #LCSM chat on Thursday, March 27th at 8 PM ET, 5 PM PT. Topics will include:
1) Do we need to identify a target before committing people, money, & time to large lung cancer trials? Should we abandon targeted therapy trials in broad populations?
2) Is tissue for testing and molecular testing available enough for targeted therapy trials, or will too many potential patients miss out? Will this be a hurdle to access?
3) Will those without any "targetable markers" be left without trial options? Will we exclude too many "molecular marker orphans"?
ASCO, the American Society for Clinical Oncology, is promoting a new principle that targeted therapies should be used only in targeted patients, as part of a general trend that we need to move away from trials that test new non-chemotherapy agents in a broad population. Meanwhile, we've just recently seen a few high profile negative trials in the last few weeks, such as the large phase III METLung trial of "METMAb" or onartuzumab, the monoclonal antibody against the target MET (mesenchymal epithelial transition), combined with Tarceva (erlotinib), and also the MAGE-A3 vaccine in the MAGRIT trial done as adjuvant treatment for resected non-small cell lung cancer.
Increasingly, our negative trials are followed by subset analyses that identify a potential subgroup that may be significant beneficiaries, often offset by larger groups that don't benefit or are even harmed. As an example, the MAGRIT trial, just reported as negative in the broad population of post-operative patients and in the subset of patients who didn't also receive adjuvant chemotherapy (the trial allowed patients to receive the vaccine or placebo either after adjuvant chemo or as the only adjuvant treatment), but the study is still looking at an investigational gene signature that may predict for significant benefit vs. non-benefit with the MAGE-A3 vaccine.
We need insights from people running trials, who would enroll patients on trials, and those seeking trial options. I hope you'll join us for a lively tweet chat Thursday evening. Just check out http://www.tchat.io/rooms/lcsm at the appointed hour, or use the twitter client of your choice and follow the hashtag #LCSM. Hope to see you then!
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Bluebird, Welcome to GRACE. I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had.
A CT would be...
Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...
Hi and welcome to GRACE. I'm sorry to know you are entering a new stage. I'm not about to comment just now but wanted to let you know I see your...
Edit to say, we can't give advice but we can comment with views and facts. :)
My first thought is to ask if she has been seen at a large...
Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...